Splenic Marginal Zone Lymphoma · line 1 · Sofosbuvir/Velpatasvir 12 weeks

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-DAA-SOF-VEL`

ID	`IND-SMZL-1L-HCV-POSITIVE`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-SPLENIC-MZL`
Sources	`SRC-BSH-MZL-2024` `SRC-EASL-HCV-2023` `SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025`

Notes

STUB — reuses HCV-MZL extranodal logic for splenic localization.

Used By

Algorithms

ALGO-SMZL-1L - ALGO-SMZL-1L

Indication

IND-SMZL-1L-RITUXIMAB - IND-SMZL-1L-RITUXIMAB